TrialBreast cancer research and treatment2012

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Martin Schuler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.